Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and republic of the Marshall Islands

Pediatric Infectious Disease Journal

Volumn 35, Issue 4, 2016, Pages 414-421

  Mase, Sundari R ^a   Jereb, John A ^a   Gonzalez, Daniel ^b,c,d   Martin, Fatma ^e   Daley, Charles L ^f   Fred, Dorina ^g   Loeffler, Ann M ^h   Menon, Lakshmy R ^a   Morris, Sapna Bamrah ^a   Brostrom, Richard ^a   Chorba, Terence ^a   Peloquin, Charles A ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e North Bay Pediatrics   (United States)

^f DEPARTMENT OF MEDICINE   (United States)

^g Federated States of Micronesia (FSM)   (United States)

^h Department of Public Health   (United States)

Author keywords

Children; Levofloxacin; Multidrug resistant; Pharmacokinetics; Tuberculosis

Indexed keywords

ETHAMBUTOL; LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; ELIMINATION HALF-LIFE; FEDERATED STATES OF MICRONESIA; FEMALE; HUMAN; INFANT; LATENT TUBERCULOSIS; MALE; MARSHALL ISLANDS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; DRUG MONITORING; MICROBIAL SENSITIVITY TEST; PRESCHOOL CHILD; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; INFANT; LATENT TUBERCULOSIS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MICRONESIA; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84949579901     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001022     Document Type: Article

References (27)

1. Liu H, Mulholland SG. Appropriate antibiotic treatment of genitourinary infections in hospitalized patients. Am J Med. 2005;118(suppl 7A):14S-20S.
2. MacDougall C, Guglielmo BJ, Maselli J, et al. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis. 2005;11:380-384.
3. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852-857.
4. European Centre for Disease Prevention and Control (ECDC). Management of Contacts of MDR TB and XDR TB Patients. Stockholm, Sweden: ECDC; 2012.
5. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51:576-582.
6. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32:101-119.
7. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol. 2005;45:153-160.
8. Thee S, Garcia-Prats AJ, McIlleron HM, et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother. 2014;58:2948-2951.
9. Bamrah S, Brostrom R, Fred D, et al. Treatment for latent tuberculosis infection in contacts to multidrug-resistant tuberculosis - Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014;18:912-918.
10. Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol. 2012;929:377-389.
11. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85-94.
12. Keizer RJ, van Benten M, Beijnen JH, et al. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72-79.
13. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143-151.
14. Sarkar D. Lattice: Multivariate Data Visualization with R. 1st ed. New York: Springer; 2008.
15. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
16. Li F, Nandy P, Chien S, et al. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother. 2010;54:375-379.
17. Levofloxacin Pharmacometrics Review: New Drug Application. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM252889.pdf. Accessed March 2013.
18. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784-791.
19. Fraser A, Paul M, Attamna A, et al. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis. 2006;10:19-23.
20. Dolui SK, Das M, Hazra A. Ofloxacin-induced reversible arthropathy in a child. J Postgrad Med. 2007;53:144-145.
21. Chalumeau M, Tonnelier S, D'Athis P, et al; Pediatric Fluoroquinolone Safety Study Investigators. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics. 2003;111(6 pt 1):e714-e719.
22. Burkhardt JE, Hill MA, Turek JJ, et al. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol. 1992;29:230-238.
23. Blumer JL. Fluoroquinolone use in children, resistance and safety implications. Contemp. Pediatr. 2003;20,97-113.
24. Smith KC, Seaworth BJ. Drug-resistant tuberculosis: controversies and challenges in pediatrics. Expert Rev Anti Infect Ther. 2005;3:995-1010.
25. Rubin MI, Bruck E, Rapoport M. Maturation of renal function in childhood; clearance studies. J Clin Invest. 1949;28(5 pt 2):1144-1162.
26. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391-408.
27. Angeby KA, Jureen P, Giske CG, et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother. 2010;65:946-952.